Biomedical subjects

Ariel Roguin

Publications and source records attributed to Ariel Roguin.

57 records · Page 4Linked to original sources

PubMed2000

Basic principles of angiogenesis for the interventional cardiologist.

Despite tremendous advances in the management of coronary artery disease, there is a growing population of patients who remain symptomatic with residual myocardial ischemia. Therapeutic angiogenesis, designed to promote the development of endogenous conduits forming collateral blood vessels that serve to bypass coronary artery stenotic lesions, may constitute an alternative treatment strategy for patients with extensive tissue ischemia in whom contemporary therapies-antianginal medications, angioplasty, bypass surgery-have failed or are not feasible. Intensive investigation is now focused on methods that would have the potential to stimulate the development of collaterals in humans. In this review we summarize the physiology of angiogenesis and its role in development and adult life, its regulation, the effects of ischemia and hypoxia, the principles of gene therapy for angiogenesis, and an update on the current available trials data of angiogenic cytokines administration.

Journal Article↗

PubMed2000

Clinical and angiographic results with the beStent: the Registry for Optimal beStent Evaluation (ROSE) trial.

BACKGROUND: Although safety and efficacy of the beStent (Medtronic Inc., Santa Rosa, CA, USA) have been described, the long-term angiographic and clinical outcomes have yet to be investigated. The ROSE (Registry for Optimal beStent Evaluation) trial was designed to assess the procedural safety of single 15 mm beStent implantation, and the six-month angiographic and 12-month clinical outcomes of patients treated with this novel coronary stent. METHODS: Patients with angina and a single de novo lesion in a native coronary artery of >/=2.75 mm diameter were included in this multicenter, prospective, observational trial. Clinical follow-up was obtained at one, six and 12 months. Angiography was performed before and after the stent implantation and at six months. The primary end-point included major adverse cardiac events (death, myocardial infarction and target lesion revascularization), major bleeding complications, and thrombotic occlusions at one-month follow-up. Secondary end-points were major cardiac-event-free survival at six- and 12-month follow-up and angiographic restenosis at six months. A total of 120 patients (80% male, mean age 58.6 +/- 10.6 years) with stable (48%) or unstable (44%) angina pectoris were allocated. The target vessel reference diameter pre-procedure was 2.85 +/- 0.52 mm. RESULTS: Minimal lumen diameter pre/post and at follow-up was 0.97 +/- 0.28 mm, 2.53 +/- 0.40 mm and 1.86 +/- 0.63 mm, respectively. Restenosis rate according to the >50% diameter stenosis criterion at six-month follow-up was 21.5%. At 12 months, the event-free survival rate was 75% (no deaths, two Q-wave and seven non-Q-wave infarctions, five bypass surgery interventions and 16 target lesion revascularizations), whilst 87% of the patients were free of angina pectoris. CONCLUSION: Despite the relatively high percentage of small vessels, the outcome of the ROSE trial is comparable to those observed in previous stent trials, indicating that the coronary beStent is safe and effective as a primary device for the treatment of native coronary artery lesions in patients with (un)stable angina pectoris.

Journal Article↗

PubMed1999

Deferring angioplasty in intermediate coronary lesions based on coronary flow criteria is safe: comparison of a deferred group to an intervention group.

The decision for revascularization in patients with intermediate coronary lesions remains a challenging topic, particularly when objective data of reversible ischemia are lacking. In some of the patients, coronary revascularization is performed or deferred without definitive evidence on the clinical significance of the coronary stenosis. We investigated the usefulness of coronary flow reserve (CFR) measurements in 28 patients with intermediate coronary lesions. We compared 20 patients who underwent angioplasty based on Doppler-wire-derived CFR with 8 patients for whom angioplasty was deferred (diameter stenosis of 50.7 +/- 2.0% versus 46.5 +/- 3.1%, P < 0.0001 and CFR of 1.80 +/- 0.32 versus 2.65 +/- 0.11, P = 0.002, respectively). Angioplasty resulted in normalization of the CFR to 2.57 +/- 0.53 (P < 0.0001, versus the baseline value). During a follow-up period of 58.1 weeks (range 23-149 weeks), eight patients in the revascularization group were readmitted to the hospital, one of them with a myocardial infarction in the territory of the target vessel, compared with only one admission in the deferred group. Target-vessel revascularization was performed in three patients (a fourth patient declined it) in the former group, compared with only one in the latter. Symptomatic improvement or no change in clinical status was observed in the majority of patients in both groups (90% in the revascularization group and 87.5% in the deferred group). We conclude that in a selected group of patients with intermediate coronary lesions, measurement of CFR may be a useful tool in determining the need for revascularization based on its physiologic significance. Importantly, deferring PTCA in patients with intermediate lesions and normal CFR values seems to be safe.

Journal Article↗